New stent trial aims to stop second strokes in Hard-to-Treat carotid disease

NCT ID NCT07166731

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a stent (CARESTO® heal) plus standard medication against medication alone in 536 people who recently had a stroke or retinal artery blockage due to a specific type of carotid artery disease that is not severely narrowed. The goal is to see if the stent can lower the chance of another stroke or eye artery blockage over the medium and long term. Participants must have had their stroke within the last two weeks and have high-risk plaque features.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CARESTO® heal Stent (a carotid artery stent) plus medical management
What this could lead to
If successful, this could offer a new treatment option to reduce the risk of recurrent stroke in people with a specific type of carotid artery disease that is not currently treated with stents.
What could go wrong
This is a mid-stage trial with 536 participants, so results are not yet proven. Stenting carries risks like stroke, bleeding, or artery damage, and the benefit over medication alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Städtisches Klinikum Solingen

    RECRUITING

    Solingen, North Rhine-Westphalia, 42653, Germany

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.